operationalgrowth News & Analysis

Zoetis (ZTS) Q3 2024 Revenue Grows 14% Operationally

In Q3 2024, Zoetis (ZTS) reported a 14% operational revenue growth, driven by a 15% increase in the U.S. and a 13% increase internationally. Adjusted net income saw a 15% operational rise, with key franchises, including the companion animal portfolio, also growing by 15%. The osteoarthritis pain franchise, consisting of Librela and Solensia, delivered a significant 97% operational revenue increase globally. This consistent growth reflects demand for their diverse and science-driven portfolio, positioned to address customer needs effectively.